Clinical Research
Protocols
Clinical Research Protocols in Combined Radiation and Chemotherapy
High Priority Trials
NCI HIGH PRIORITY CLINICAL TRIAL EST-3590 Phase III Comparison of Thoracic
Radiotherapy Alone vs Combined With CDDP/ VP-16 Chemotherapy as Postoperative Adjuvant
Therapy for Stage II/IIIA Nonsmall Cell Lung Cancer (Summary last modified 01/95).
Chairman: Steven M. Keller, Beth Israel Medical Center, New York, NY. Lead organization:
Eastern Cooperative Oncology Group. Acceptable age range: 18 and over.
NCI HIGH PRIORITY CLINICAL TRIAL SWOG-9008 Phase III Randomized Study of
Adjuvant Chemoradiotherapy With 5-FU/CF in Patients With Resected Gastric Cancer (Summary
last modified 03/95).
Chairman: John S. MacDonald, Temple University Medical Center, Philadelphia, Pa. Lead
organization: Southwest Oncology Group. Ac-ceptable age range: any age.
NCI HIGH PRIORITY CLINICAL TRIAL RTOG-9309 Phase III Randomized Study of
Concurrent Radiotherapy and CDDP/VP-16 With vs Without Surgical Resection for Stage IIIA
(N2) Nonsmall Cell Lung Cancer (Summary last modified 04/96).
Chairman: David S. Ettinger, Johns Hopkins Oncology Center, Baltimore, Md. Lead
organization: Radiation Therapy Oncology Group. Acceptable age range: 18 and over.
NCI HIGH PRIORITY CLINICAL TRIAL NCCTG-914652 Phase III Randomized Trial of
Adjuvant 5-FU/LEV With vs Without Radiotherapy in Patients With Completely Resected
Adenocarcinoma of the Colon at High Risk of Locoregional Recurrence (Summary last modified
06/96).
Chairman: Michael J. O'Connell, Mayo Clinic, Rochester, Minn. Lead organization: North
Central Cancer Treatment Group. Acceptable age range: 18 and over.
NCI HIGH PRIORITY CLINICAL TRIAL RTOG-9111 Phase III Randomized Trial of
Laryngeal Preservation With CDDP/5-FU Followed by Radiotherapy vs Concomitant Radiotherapy
and CDDP vs Radiotherapy Alone in Patients With Stage III/IV Squamous Cell Cancer of the
Glottic and Supraglottic Larynx (Summary last modified 03/95).
Chairman: Helmuth Goepfert, University of Texas, M.D. Anderson Cancer Center, Houston,
Tex. Lead organization: Radiation Therapy Oncology Group. Acceptable age range: 18 and
over.
Other Trials
RTOG-9001 Phase III Comparison of Pelvic Irradiation With Concurrent CDDP/5-FU
vs Pelvic and Para-Aortic Irradiation Without Chemotherapy in Patients With High-Risk
Carcinoma of the Cervix (Summary last modified 04/93).
Chairman: Mitchell Morris, University of Texas, M.D. Anderson Cancer Center, Houston, Tex.
Lead organization: Radiation Therapy Oncology Group. Acceptable age range: 18 and over.
RTOG-9401 Phase III Intergroup Randomized Study of Preoperative vs Postoperative
Combined 5-FU/ CF and Radiotherapy for Resectable Rectal Adenocarcinoma (Summary last
modified 11/95).
Chairman: Bruce D. Minsky, Memorial Sloan-Kettering Cancer Center, New York, NY. Lead
organization: Radiation Therapy Oncology Group. Acceptable age range: 18 and over.
SWOG-8797 Phase III Randomized Comparison of Radiotherapy With vs Without
Continuous Infusion 5-FU/Bolus CDDP Following Radical Hysterectomy and Node Dissection in
High-Risk Patients With Stages IA2, IB, and IIA Carcinoma of the Cervix (Summary last
modified 02/96).
Chairman: William A. Peters III, First Hill Women's Clinic, Seattle, Wash. Lead
organization: Southwest Oncology Group. Acceptable age range: any age.
SWOG-9304 Phase III Randomized Study of Adjuvant 5-FU in Patients With Stages
B2/B3/C Rectal Cancer: Bolus vs Prolonged Venous Infusion (PVI) 5-FU Before and After
Pelvic Irradiation, Each With PVI 5-FU Radiosensitization, vs Bolus 5-FU/CF/LEV Before and
After Radiotherapy With Bolus 5-FU/CF Radiosensitization (Summary last modified 05/96).
Chairman: Stephen R. Smalley, Therapeutic Radiologists, Inc, Kansas City, Mo. Lead
organization: Southwest Oncology Group. Acceptable age range: over 18.
RTOG-9405 Phase III Randomized Study of CDDP/5-FU Plus High- Dose vs
Conventional-Dose Radiotherapy for Carcinoma of the Esophagus (Summary last modified
05/96).
Chairman: Bruce D. Minsky, Memorial Sloan-Kettering Cancer Center, New York, NY. Lead
organization: Radiation Therapy Oncology Group. Acceptable age range: 18 and over.
RTOG-9304 Phase III Randomized Study of Conventional Radiotherapy With vs
Without IFN-beta in Patients With Locally Advanced Nonsmall Cell Lung Cancer (Summary last
modified 04/96).
Chairman: Philip Rubin, University of Rochester Cancer Center, Rochester, NY. Lead
organization: Radiation Therapy Oncology Group. Acceptable age range: 18 and over.
RTOG-9501 Phase III Randomized Study of Postoperative Radiotherapy With vs
Without CDDP for Resectable High-Risk Squamous Cell Carcinoma of the Head and Neck
(Summary last modified 11/95).
Chairman: Jay Scott Cooper, NYU Medical Center, New York, NY. Lead organization: Radiation
Therapy Oncology Group. Acceptable age range: 18 and over.
RTOG-9305 Phase III Randomized Study of Radiosurgery Followed by Conventional
Radiotherapy With BCNU vs Conventional Radiotherapy With BCNU in Patients With
Supratentorial Glioblastoma Multiforme (Summary last modified 05/96).
Chairman: Luis Souhami, Montreal General Hospital, Montreal, Quebec, Canada. Lead
organization: Radiation Therapy Oncology Group. Acceptable age range: 18 and over.
RTOG-9404 Phase III Randomized Study of Radiotherapy With vs Without BUDR and
Followed by PCV (PCB/CCNU/VCR) for Anaplastic Astrocytomas (Summary last modified 09/95).
Chairman: Michael Del Prados, University of California-San Francisco. Lead organization:
Radiation Therapy Oncology Group. Acceptable age range: 18 and over.
RTOG-9410 Phase III Randomized Study of Standard Thoracic Irradiation Following
VBL/CDDP vs Standard Thoracic Irradiation and Concurrent VBL/CDDP vs Hyperfractionated
Thoracic Irradiation and Concurrent VP-16/CDDP for Locally Advanced, Unresectable,
Non-small Cell Lung Cancer (Summary last modified 04/95).
Chairman: Walter J. Curran, Jr, Jefferson Medical College, Philadelphia, Pa. Lead
organization: Radiation Therapy Oncology Group. Acceptable age range: 18 and over.
RTOG-9506 Phase I/II Multimodal Therapy for Stage II/III Bladder Cancer
Following TUR: Induction With CDDP/5-FU/Irradiation (CFI) Followed by Consolidation CFI
for Complete Responders or by Radical Cystectomy for Residual Disease (Summary last
modified 12/95).
Chairman: William U. Shipley, Cox Cancer Center, Massachusetts General Hospital, Boston,
Mass. Lead organization: Radiation Therapy Oncology Group. Acceptable age range: 18 and
over.
RTOG-9209 Phase I/II Study of Hyperfractionated External-Beam Radiotherapy,
Prophylactic Hepatic Radiotherapy, and Concurrent 5-FU/Low-Dose CF in Patients With
Unresectable Carcinoma of the Pancreas (Summary last modified 08/95).
Chairman: Christopher G. Willett, Massachusetts General Hospital, Boston, Mass. Lead
organization: Radiation Therapy Oncology Group. Acceptable age range: 18 and over.
RTOG-9310 Phase II Intergroup Study of Combined Modality Therapy Using
MTX/VCR/PCB/DM Followed by Radiotherapy Plus ARA-C for Primary CNS Lymphoma (Summary last
modified 09/95).
Chairman: Lisa Marie DeAngelis, Memorial Sloan-Kettering Cancer Center, New York, NY. Lead
organization: Radiation Therapy Oncology Group. Acceptable age range: over 18.
RTOG-9417 Phase II Study of Radiotherapy With Tirapazamine Radiosensitization
for Glioblastoma Multiforme (Summary last modified 07/96).
Chairman: John Del Rowe, Montefiore Medical Center, Bronx, NY. Lead organization:
Radiation Therapy Oncology Group. Acceptable age range: 18 and over.
RTOG-9507 Phase I Study of Topotecan Plus Cranial Radiotherapy for Glioblastoma
Multiforme (Summary last modified 01/96).
Chairman: James D. Cox, University of Texas M.D. Anderson Cancer Center, Houston, Tex.
Lead organization: Radiation Therapy Oncology Group. Acceptable age range: 18 and over.
RTOG-9502 Phase IB Study of Radiosurgery Plus SR-2508 for Recurrent Primary
Brain Tumors or CNS Metastases (Summary last modified 01/96).
Chairman: James D. Cox, University of Texas M.D. Anderson Cancer Center, Houston, Tex.
Lead organization: Radiation Therapy Oncology Group. Acceptable age range: 18 and over.
Legend for Abbreviations
EST = Eastern Cooperative Oncology Group
NCCTG = North Central Cancer Treatment Group
RTOG = Radiation Therapy Oncology Group
SWOG = Southwest Oncology Group
Back to Cancer Control
Journal Volume 3 Number 4